Year-over-year earnings per share growth for the last twelve months: Sutro Biopharma, Inc. (STRO)

sutrobio.com (STRO) - corporate logo

Sutro Biopharma, Inc. (STRO) faces high losses and the risk of clinical trial failures, forcing the company to conduct secondary offerings. This quarterly EPS chart illustrates profit dynamics, where the indicator value stands at -71.40. The development of innovative drugs relies on partnerships with pharma behemoths. However, business sustainability depends on platform validation and external financing while maintaining liquidity control.

Sutro Biopharma Inc. (STRO) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/13/2026

Comprehensive metric breakdowns and analytics for Sutro Biopharma, Inc (STRO)

- share price and expert price forecast:
Stock Price Sutro Biopharma|STRO - Analyst Median Target
- company stock exchange capitalization indicators:
Market Value Sutro Bio|STRO - Real Price to Acquire Entire Company
- book capitalization data:
Net Assets per Single Share Sutro Biopharma|STRO - Company Net Assets|Market Cap to Net Assets Ratio sutrobio.com|STRO - Company Total Assets
- debt and liquidity details:
Debt to Equity Sutro Biopharma, Inc.|STRO - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Sutro Biopharma, Inc.|STRO - Company Cumulative Debt|Debt to Book Value Sutro Bio|STRO - Long-Term Indebtedness|Company Current Liabilities Sutro Biopharma|Quick Ratio sutrobio.com
- earnings and market multiples details:
STRO - Final Profit|Projected Future Earnings Sutro Biopharma, Inc.|STRO - Market Cap to Earnings|Future Price to Earnings Sutro Bio|STRO - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Sutro Bio|STRO - Operating profit EBITDA|Earnings per share for the last twelve months Sutro Biopharma|STRO - Earnings per one share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months sutrobio.com|STRO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Sutro Biopharma, Inc.
Comprehensive company analysis:Sutro Biopharma, STRO
Manufactured product of Sutro Biopharma, Inc.

The complexity of developing cancer immunotherapy and the high cost of clinical trials at Sutro Biopharma, Inc. (STRO) make the analysis of quarterly EPS dynamics critical for assessing business viability. This indicator measures the percentage deviation of net income per share for the current quarter compared to the same period last year, enabling the identification of the real efficiency of patent capitalization and the company's resilience to operational risks.

Competitors of Sutro Biopharma, Inc.

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Janux Pharma|Year-over-year net earnings per share growth for the last 12 months Arcus Corp (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc. (ZYME)|Year-over-year net earnings per share growth for the last 12 months tangotx.com TNGX|Iovance Biotherapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics NV IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (Compass Therapeutics Corp) - Year-over-year earnings per share growth for the last 12 months|Replimune Group, Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months lyell.com (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months CGEN (Compugen Ltd.)|Year-over-year earnings per share growth rate for the last twelve months IOBT|Quarterly EPS earnings growth INKT (MiNK Therapeutics, Inc.)|Year-over-year earnings per one share growth for the last 12 months HOWL|Immix - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months alxoncology.com|Cue Biopharma (CUE) - Year-over-year earnings per share growth for the last twelve months|PDS Biotechnology Corporation - Year-over-year earnings per one share growth for the last 12 months|SONN (Sonnet BioTherapeutics Holdings, Inc.) - Quarterly EPS earnings growth|Quarterly EPS earnings growth MAIABiotech.com|Year-over-year earnings per share growth for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Year-over-year net earnings per share trend for the last twelve months|NextCure Corp - Year-over-year net earnings per share growth for the last 12 months|Leap Therapeutics Inc (LPTX) - Earnings per share growth in annualized terms for the last twelve months|INTS - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Sensei Biotherapeutics SNSE|TOVX (Theriva Biologics) - Year-over-year net earnings per share growth for the last 12 months|Gritstone bio (GRTS) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months KA|NEXI (NexImmune Corporation) - Year-over-year earnings per share growth rate for the last twelve months|Year-over-year earnings per share growth for the last twelve months Turnstone Biologics (TSBX)|VCNX (vaccinex.com) - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Harpoon Therapeutics, Inc. HARP